Across 19,000 real-world treatments, ChondroFiller records no serious adverse device effects and a reoperation rate of 3–8%, compared to 41% for microfracture and 37% for ACI/MACI.Across 19,000 real-world treatments, ChondroFiller records no serious adverse device effects and a reoperation rate of 3–8%, compared to 41% for microfracture and 37% for ACI/MACI.
:format(webp)/cdn.mskdoctors.com/storage/2026/6/g4jeoAaCgWErjXOQATNvsVK1IZqAujmg.jpg)
